Session » Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)

Date: Saturday, November 6, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 0408

A Histogram-based Densitometry Index to Support the Identification and the Assessment of Severity of Interstitial Lung Disease in Systemic Sclerosis: Applicability in Conventional and Low-dose Computed Tomography

8:30AM-10:30AM: Abstract Number: 0403

Effect of Nintedanib on KL-6 in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

8:30AM-10:30AM: Abstract Number: 0396

Esophageal Involvement and Gastroesophageal Reflux Disease in Patients with SSc-ILD: Data from a Sub-Study of the SENSCIS Trial

8:30AM-10:30AM: Abstract Number: 0409

Factors Predicting Mortality in an Indian Cohort of Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 0392

Faecal Incontinence in Scleroderma: Prevalence, Impact and Response to Sacral Neuromodulation in an Single Centre Observational Cohort

8:30AM-10:30AM: Abstract Number: 0406

Gender Differences in Clinical Features and Outcomes of Systemic Sclerosis: Analysis of Reuma.pt/SSc Registry

8:30AM-10:30AM: Abstract Number: 0391

High Frequency Ultrasound Imaging of Skin Thickness in Patients with Early Diffuse Cutaneous Systemic Sclerosis: An Objective Outcome Measure to Track Change over Time

8:30AM-10:30AM: Abstract Number: 0394

Hyperspectral Imaging in Systemic Sclerosis-Raynaud Phenomenon

8:30AM-10:30AM: Abstract Number: 0400

Item Development for the Assessment of Systemic Sclerosis-associated Raynaud’s Phenomenon (ASRAP) Questionnaire

8:30AM-10:30AM: Abstract Number: 0401

Item Reduction for the Assessment of Systemic Sclerosis-associated RAynaud’s Phenomenon (ASRAP) Questionnaire Using Data from the International Multicentre ASRAP Validation Study

8:30AM-10:30AM: Abstract Number: 0410

Long-term Outcomes of Vascular Grafting of Medium Sized Vessels of the Wrist and Hand in Patients with Medication Refractory Systemic Sclerosis Related Raynaud’s Phenomenon at the University of Pennsylvania from 2009-2019

8:30AM-10:30AM: Abstract Number: 0399

Nailfold Videocapillaroscopy Findings and Associations with Organ Involvement in Mixed Connective Tissue Disease

8:30AM-10:30AM: Abstract Number: 0398

Performance of ACR CRISS Score and Revised ACR CRISS Response in a Phase 3 Trial of Lenabasum in Diffuse Cutaneous Systemic Sclerosis (dcSSc) in Which Background Immunosuppressive Therapies (bIST) Were Allowed

8:30AM-10:30AM: Abstract Number: 0404

Perifollicular Hypopigmentation in Systemic Sclerosis: Associations with Clinical Features and Internal Organ Involvement

8:30AM-10:30AM: Abstract Number: 0411

Pharmacokinetics, Safety, and Efficacy of Subcutaneous Brodalumab for Systemic Sclerosis with Moderate-to-severe Skin Thickening: A Single-arm, Open-label, Multi-dose, Phase 1 Trial

8:30AM-10:30AM: Abstract Number: 0388

Prediction Tool for Damage Accrual Trajectory in Incident Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 0387

Predictors for Progressive Fibrosis in Patients with Connective Tissue Disease Associated Interstitial Lung Diseases

8:30AM-10:30AM: Abstract Number: 0413

Predictors of ILD Development and Timing of Onset in Systemic Sclerosis: A Canadian Cohort

8:30AM-10:30AM: Abstract Number: 0412

Prevalence, Distribution, Clinical Correlates and Outcomes of Upper Extremity Macrovascular Disease in Systemic Sclerosis: Results from a Single Center Referral Cohort (2001-2018)

8:30AM-10:30AM: Abstract Number: 0405

Retrospective Study on the Prognostic Value of Cardiac Magnetic Resonance Imaging Abnormalities in Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 0395

RNA Polymerase III Autoantibody Levels and Risk of Systemic Sclerosis in Patients with Raynaud Phenomenon

8:30AM-10:30AM: Abstract Number: 0397

Safety and Persistence of Monthly Intravenous Iloprost in Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 0393

Severity and Impact of Gastrointestinal Symptoms in Patients with SSc-ILD Treated with Nintedanib: Data from SENSCIS-ON

8:30AM-10:30AM: Abstract Number: 0407

The Clinical Role of T1 Mapping Cardiac Magnetic Resonance Imaging for Detecting Cardiac Involvement in the Early Stage of Systemic Sclerosis

8:30AM-10:30AM: Abstract Number: 0389

Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States

8:30AM-10:30AM: Abstract Number: 0390

Vaccination Against COVID-19: Self-Reported Experiences of Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort

8:30AM-10:30AM: Abstract Number: 0402

What Is the Patient’s Perspective on Symptoms Experience in Limited Cutaneous Systemic Sclerosis?

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].